Dianthus Therapeutics (DNTH) EBIT Margin: 2022-2025
Historic EBIT Margin for Dianthus Therapeutics (DNTH) over the last 3 years, with Sep 2025 value amounting to -10,173.74%.
- Dianthus Therapeutics' EBIT Margin fell 879713.00% to -10,173.74% in Q3 2025 from the same period last year, while for Sep 2025 it was -4,558.41%, marking a year-over-year decrease of 300445.00%. This contributed to the annual value of -1,633.74% for FY2024, which is 7093.00% up from last year.
- According to the latest figures from Q3 2025, Dianthus Therapeutics' EBIT Margin is -10,173.74%, which was up 43.78% from -18,096.89% recorded in Q2 2025.
- In the past 5 years, Dianthus Therapeutics' EBIT Margin registered a high of -703.67% during Q3 2022, and its lowest value of -18,096.89% during Q2 2025.
- Moreover, its 3-year median value for EBIT Margin was -2,041.65% (2024), whereas its average is -4,145.58%.
- Per our database at Business Quant, Dianthus Therapeutics' EBIT Margin soared by 63,438bps in 2024 and then tumbled by 1,690,505bps in 2025.
- Over the past 4 years, Dianthus Therapeutics' EBIT Margin (Quarterly) stood at -910.04% in 2022, then slumped by 213,127bps to -3,041.31% in 2023, then soared by 63,438bps to -2,406.94% in 2024, then crashed by 879,713bps to -10,173.74% in 2025.
- Its last three reported values are -10,173.74% in Q3 2025, -18,096.89% for Q2 2025, and -2,852.71% during Q1 2025.